Pangaea Oncology raises €12 million to accelerate its growth
Pangaea Oncology, linked to the Barcelona Science Park as an associated company, carried out one of the most significant operations of this year on the Spanish BME Growth stock market. The company, a leader in precision oncology medical services, has secured €12 million through two capital increases. These funds will go towards accelerating its organic and inorganic strategic growth.
The new shareholders, which Pangaea scouted for with help from Banca March, were notably led by important institutional investors, such as Eléctrica del Oeste of Extremadura, Irigen of Zaragoza, and Mirling Europe and Projecte Asfodel from Barcelona. All acquired more than a 5% stake in the company, highlighting their confidence in the company.
Top Pangaea executives endorse this new push and are plotting the strategic path to follow. “Thanks to these operations we’ll be able to drive the company’s inorganic growth, and to move into national markets we don’t currently operate in,” notes the company’s corporate and financial general manager, Alejandro García Moncayo.
Through its subsidiaries Instituto Oncológico Dr. Rosell (IOR), Quenet Torrent Institute (QTI), and the International Breast Cancer Center, Pangaea provides comprehensive personalised oncology management, present at several hospitals in Barcelona.
Pangaea also has a latest-generation laboratory that provides molecular diagnostics and preclinical services to large international pharma groups.
» More information on the Pangaea Oncology website [+]